Serum neurofilament light chain, cognition and neuropsychiatric symptoms in multiple sclerosis


  • For multiple sclerosis (MS) patients with modest clinical manifestations and no acute disease activity, serum neurofilament light chain (sNfL) levels are not a surrogate biomarker for cognitive performance and neuropsychiatric symptoms.

Why this matters

    Traditional measures of MS disease activity and burden do not relate to cognitive and neuropsychiatric status, thus new biomarkers are needed to assess axonal tissue damage and potentially predict clinical outcomes.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.